Equities

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)46.02
  • Today's Change-0.38 / -0.82%
  • Shares traded525.62k
  • 1 Year change+18.49%
  • Beta0.5618
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy7
Outperform13
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 21 analysts offering 12 month price targets for Ultragenyx Pharmaceutical Inc have a median target of 83.00, with a high estimate of 140.00 and a low estimate of 48.00. The median estimate represents a 80.36% increase from the last price of 46.02.
High204.2%140.00
Med80.4%83.00
Low4.3%48.00

Earnings history & estimates in USD

On Nov 05, 2024, Ultragenyx Pharmaceutical Inc reported 3rd quarter 2024 losses of -1.40 per share. This result was in line with the consensus of the 18 analysts following the company and exceeded last year's 3rd quarter results by 37.22%.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate+7.83%
Ultragenyx Pharmaceutical Inc reported annual 2023 losses of -8.25 per share on Feb 15, 2024.
Average growth rate-23.48%
More ▼

Revenue history & estimates in USD

Ultragenyx Pharmaceutical Inc. had 3rd quarter 2024 revenues of 139.49m. This bettered the 135.79m consensus of the 16 analysts covering the company. This was 38.81% above the prior year's 3rd quarter results.
Average growth rate+11.33%
Ultragenyx Pharmaceutical Inc. had revenues for the full year 2023 of 434.25m. This was 19.52% above the prior year's results.
Average growth rate+53.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.